MedDataX Logo

The Management of Schizophrenia in Clinical Practice (MOSAIC)

NCT ID: NCT01746134

Last Updated: 2016-11-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

557 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-12-31

Study Completion Date

2014-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a disease-based registry designed to follow patients with a DSM-IV-TR (Diagnostic and Statistic Manual of Mental Disorders, Text Revision) diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder treated in usual care settings for up to 5 years. The registry seeks to describe the course of disease in schizophrenia, including cognitive function and negative symptoms, its treatment, and its burden of disease for participants, caregivers, clinicians, and society as a whole.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients, \>/= 18 years of age
* DSM-IV-TR diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder
* Participants presenting with the normal course of care in usual treatment settings
* Able to read and speak English
* Able and willing to provide informed consent
* Able and willing to comply with the study protocol

Exclusion Criteria

* Participants enrolled as subjects in clinical trials at registry enrollment
* Participants anticipating they will be unable to participate in regularly scheduled assessments as per protocol
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Genentech, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Trials

Role: STUDY_DIRECTOR

Genentech, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Granada Hills, California, United States

Site Status

Los Angeles, California, United States

Site Status

Santa Monica, California, United States

Site Status

Cedar Rapids, Connecticut, United States

Site Status

New Haven, Connecticut, United States

Site Status

Chicago, Florida, United States

Site Status

Gainesville, Florida, United States

Site Status

Gainesville, Florida, United States

Site Status

Gainesville, Florida, United States

Site Status

Jacksonville, Florida, United States

Site Status

Lake City, Florida, United States

Site Status

Miami, Florida, United States

Site Status

Miami, Florida, United States

Site Status

Chicago, Illinois, United States

Site Status

Iowa City, Iowa, United States

Site Status

Iowa City, Iowa, United States

Site Status

Iowa City, Iowa, United States

Site Status

Belmont, Massachusetts, United States

Site Status

Minneapolis, Minnesota, United States

Site Status

Saint Paul, Minnesota, United States

Site Status

Saint Paul, Minnesota, United States

Site Status

New York, New York, United States

Site Status

New York, New York, United States

Site Status

New York, New York, United States

Site Status

New York, New York, United States

Site Status

New York, New York, United States

Site Status

New York, New York, United States

Site Status

Orangeburg, New York, United States

Site Status

Carrboro, North Carolina, United States

Site Status

Cary, North Carolina, United States

Site Status

Chapel Hill, North Carolina, United States

Site Status

Durham, North Carolina, United States

Site Status

Durham, North Carolina, United States

Site Status

Durham, North Carolina, United States

Site Status

Hillsborough, North Carolina, United States

Site Status

Pinehurst, North Carolina, United States

Site Status

Cincinnati, Ohio, United States

Site Status

Lytle, Texas, United States

Site Status

Round Rock, Texas, United States

Site Status

San Antonio, Texas, United States

Site Status

San Antonio, Texas, United States

Site Status

Taylor, Texas, United States

Site Status

Salt Lake City, Utah, United States

Site Status

Tacoma, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ML28264

Identifier Type: -

Identifier Source: org_study_id